CMAB Biopharma Secures $34-Million Financing, Announces Collaborations

CMAB Biopharma Inc. recently announced the company has raised $34 million in Series B financing. The round is being led by CD Capital, and jointly participated by C-Bridge Capital, Cormorant, Qianhai FoF Fund and Tigermed. The funding proceeds will be used to upgrade CMAB’s 2,000L Good Manufacturing Practices (GMP) facilities, expand manufacturing capacity and will also enable the company to provide 50L/200L/500L/1,000L/2,000L bioreactor scale GMP manufacturing services.

Located in Suzhou’s BioBAY Park, CMAB’s new manufacturing facility will provide services for the development of manufacturing process, analytical method, formulation, and the manufacture of biologic drug substances and drug products. The initial facility will be able to generate preclinical and early stage clinical (Phase I/II) products, using manufacturing that follows global GMP standards, including those of the China Food & Drug Administration, US Food & Drug Administration (21 CFR), European Medicines Agency (Eudralex), WHO, and harmonized PIC/S and ICH standards.

In the company’s recent grand opening, CMAB also announced it has entered into collaboration agreements with several leading biopharma companies, which speaks to the quality of CMAB’s services and to the expertise of its management team.

“The closing of this round is an important milestone for CMAB and reflects the significant achievements we have made in developing the company into a preferred CDMO partner,” said Qibin Liang, President of CMAB. “We aim to bring our client expertise and knowledge to efficiently advance products from concept into the clinic. This financing furthers our vision to become a fully integrated CDMO platform providing clinical and commercial production services to the Chinese domestic and the international biologics markets.”

Qing Tan, founding partner of CD Capital, said “CMAB has quickly established itself as a force in CDMO industry. We are delighted to lead this financing and support CMAB in its mission to enable clients to take their innovative concepts for tomorrow’s medicines from DNA to clinical product today, not only in China, but globally. It is well accorded with CD Capital’s investment strategy.”

CMAB is a flexible full-service CDMO dedicated to providing bespoke development manufacturing services of antibodies and biologics for clients in China and across the globe. Our adaptable, service-oriented business enables clients to take their innovative concepts for tomorrow’s medicines from DNA to clinical product today. For more information, visit www.cmabbio.com.

CD Capital is a venture capital founded in 2013, specialized in the medical and healthcare investment. It is currently managing multiple USD and RMB funds, with asset under management of over RMB 4 Billion. CD Capital is operated by a professional team with diversified and profound industry background. It has made investment in more than 30 high-potential companies and realized multiple exits. CD Capital benefits from China market by leveraging global technology and business model. For more information, visit http://www.cd-pe.com.

C-Bridge Capital is a healthcare dedicated private equity firm, focused on growth and late stage investment opportunities with US$800 million of Assets Under Management. C-Bridge Capital’s current portfolio includes China’s leading players in pharmaceuticals, medical devices, diagnostics and healthcare services. C-Bridge Capital is committed to support commercialization of cutting edge technologies and companies that fulfill unmet medical needs, thus continuously improving the standard and quality of care for patients. For more information, visit www.cbridgecap.com.